Key result
DOACs and VKAs altered thromboelastometry and thrombin generation differently, with clotting time and endogenous thrombin potential strongly correlating with DOAC concentrations or VKA-INR.
Why the study?
Alterations induced by direct oral anticoagulants or vitamin K antagonists to thromboelastometry and thrombin generation were not well defined.
Do direct oral anticoagulants and vitamin K antagonists differentially alter thromboelastometry and thrombin generation in chronically anticoagulated patients?
Cross-Sectional (n=164)
Do direct oral anticoagulants and vitamin K antagonists differentially alter thromboelastometry and thrombin generation in chronically anticoagulated patients?
Thromboelastometry clotting time and endogenous thrombin potential strongly correlate with DOAC concentrations and may serve as surrogate tests for evaluating anticoagulation levels when dedicated assays are unavailable.
May support thromboelastometry and thrombin generation as anticoagulation surrogates; leaves open prospective validation before clinical adoption.
Background. Alterations induced by direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs) to thromboelastometry and thrombin generation are not well defined. We performed a simultaneous investigation of thromboelastometry and thrombin generation for patients who were chronically anticoagulated with DOACs or VKAs. Methods. A total of 131 patients on DOACs [apixaban (n = 37), rivaroxaban (n = 34), dabigatran (n = 30), edoxaban (n = 30)] and 33 on VKAs were analyzed. Whole blood was analyzed for thromboelastometry and plasma was analyzed for thrombin generation. Results. While the thromboelastometry clotting time (CT) was responsive to the hypocoagulability induced by DOACs or VKAs, clot formation time and maximal clot formation were not. Cumulatively, the parameters denoting the velocity of thrombin generation (lag time, time-to-peak) were relatively less responsive to the hypocoagulability induced by VKAs than DOACs. Conversely, the parameters denoting the quantity of thrombin generation [peak-thrombin and the endogenous thrombin potential (ETP)] were more responsive to the hypocoagulability induced by VKAs than DOACs. Apixaban showed relatively small differences (peak vs. trough) in the plasma concentration and a relatively small (peak vs. trough) difference of hypocoagulability when assessed by the CT or the ETP. The CT and the ETP were strongly correlated with DOAC concentrations or with the VKA-INR. Conclusions. DOACs and VKAs altered thromboelastometry and thrombin generation to an extent that probably reflects the mode of action of these drugs and may also have practical implications for patients’ management. Apixaban showed a small difference of hypocoagulability (peak vs. trough), suggesting a more stable anticoagulation over the daily course of treatment. Based on the correlations of the CT or the ETP vs. the DOAC concentrations, we estimated that critical values of the CT or the ETP would correspond to DOAC concentrations of 400 or 20 ng/mL. Whenever dedicated tests for DOAC concentrations are not available, the CT or the ETP can be used as surrogates to evaluate the level of anticoagulation induced by DOACs.
No takes yet. Share an insight, caveat, or question.
Tripodi et al. (2024) conducted a cross-sectional in Chronic anticoagulation (n=164). Direct oral anticoagulants (DOACs) vs. Vitamin K antagonists (VKAs) was evaluated on Thromboelastometry and thrombin generation parameters. DOACs and VKAs altered thromboelastometry and thrombin generation differently, with clotting time and endogenous thrombin potential strongly correlating with DOAC concentrations or VKA-INR.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: